Gastro-oesophageal Reflux Disease Trial, Recruiting NCT06953986 Sponsor: Asian Institute of Gastroenterology, India Condition: Gastro-oesophageal Reflux Disease
Back to Gord

Gastro-oesophageal Reflux Disease Trial, Recruiting

NCT06953986
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who have had reflux esophagitis (irritation and inflammation of the food pipe caused by stomach acid) confirmed by a camera examination of the stomach, graded as moderate to severe (LA grade B, C, or D)
  • People who have been experiencing heartburn or acid reflux symptoms for at least 4 weeks before joining the trial
  • People who are willing to give their agreement to participate and follow the study procedures

Who may not be able to join:

  • People who have used the medications Vonaprazan or Esomeprazole in the past 4 weeks
  • People who have previously had surgery on their food pipe or radiation treatment to that area
  • People who have Barrett's esophagus (a change in the lining of the food pipe), a narrowing of the food pipe, or any cancer in that area
  • Women who are pregnant or currently breastfeeding
  • People with a history of acid reflux that did not respond to standard acid-reducing medications, or a condition where the stomach empties very slowly (severe gastroparesis)
  • People with significant liver or kidney problems, based on specific blood and kidney function test results (confirm with trial site)
  • People currently using anti-inflammatory painkillers (NSAIDs), steroids, or blood-thinning medications that may interfere with healing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mohan Dr Ramchandani, MD DM, Asian Institute of Gastroenterology

Phone: 04023378888

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Asian Institute of Gastroenterology, India
Registry
ClinicalTrials.gov
Start date
20 December 2025
Est. completion
20 November 2026

Where this trial is recruiting

🇮🇳 India

Primary endpoints

• Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).; Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov